Jeonghee Cho,Liang Chen,Naveen F. Sangji,Takafumi Okabe,Kimio Yonesaka,Joshua M. Francis,Richard Flavin,William L. Johnson,Jihyun Kwon,Shan Yu,Heidi Greulich,Bruce E. Johnson,Michael J. Eck,Pasi A. Jänne,Kwok-Kin Wong,Matthew Meyerson

Abstract:PDF file - 303K, L704N or I941R cis mutation disrupts constitutive dimerization of mutant EGFR (S1); Tyrosine-phosphorylation is abrogated on L704N or I941R compound mutants of dimerization-dependent mutants (S2); Wild-type EGFR, but not Ex20Ins mutant are dependent on asymmetric dimerization for oncogenic transformation (S3); Tyrosine-phosphorylation on dimerization-independent mutants is significantly impaired by introduction of receiver-impairing or activator-impairing mutation (S4); Cell surface expression levels of various EGFR mutants in NIH-3T3 cells (S5); Activities of receiver monomers and activator monomers of wild-type EGFR (S6); Cell surface expression of mutant EGFR in stable cell lines (S7); Differential pharmacological effects of gefitinib and cetuximab against distinct mutant EGFR (S8); Generation and characterization of bitransgenic mice with inducible expression of EGFR Ex20Ins in lung compartments (S9); Cetuximab downregulates tyrosine phosphorylation on mutant EGFR in mouse tumors (S10).

Supplemental Figure 5 from SMAD4 Loss is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells

Supplemental Figure 4 from SMAD4 Loss is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells

Supplemental Figure 2 from SMAD4 Loss is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 4 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure 5 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figures 6 - 7 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Fig. 4 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 2 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure 3 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Figure S7 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Figure 2 from Cooperativity of E-cadherin and Smad4 Loss to Promote Diffuse-Type Gastric Adenocarcinoma and Metastasis

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplementary Figures 1 - 10 from Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants is Associated with Asymmetric Dimerization

Supplementary Figure S14 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer